These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

747 related items for PubMed ID: 19053049

  • 21. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
    Chou KM, Huang BY, Fanchiang JK, Chen CH.
    Chang Gung Med J; 2007; 30(6):538-46. PubMed ID: 18350737
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Nutrition in pathophysiology and treatment of nonalcoholic fatty liver disease.
    Moschen AR, Tilg H.
    Curr Opin Clin Nutr Metab Care; 2008 Sep; 11(5):620-5. PubMed ID: 18685459
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.
    Hookman P, Barkin JS.
    Am J Gastroenterol; 2003 Sep; 98(9):2093-7. PubMed ID: 14499793
    [Abstract] [Full Text] [Related]

  • 30. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.
    Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR.
    Hepatology; 2003 Oct; 38(4):1008-17. PubMed ID: 14512888
    [Abstract] [Full Text] [Related]

  • 31. Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease.
    Tilg H, Moschen A.
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):159-67. PubMed ID: 20485253
    [Abstract] [Full Text] [Related]

  • 32. Compliance, behavior change, and weight loss with orlistat in an over-the-counter setting.
    Schwartz SM, Bansal VP, Hale C, Rossi M, Engle JP.
    Obesity (Silver Spring); 2008 Mar; 16(3):623-9. PubMed ID: 18239553
    [Abstract] [Full Text] [Related]

  • 33. Orlistat.
    Wong NN, Cheng-Lai A.
    Heart Dis; 2000 Mar; 2(2):174-81. PubMed ID: 11728255
    [Abstract] [Full Text] [Related]

  • 34. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.
    Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, Podevin P, Lacorte JM, Bernhardt C, Bruckert E, Grimaldi A, Poynard T, LIDO Study Group.
    Gastroenterology; 2008 Jul; 135(1):100-10. PubMed ID: 18503774
    [Abstract] [Full Text] [Related]

  • 35. Orlistat use in overweight women with mild hypercholesterolemia.
    Petrogiannopoulos C, Kalogeropoulos S, Latsios GS, Hartzoulakis G, Kalogeropoulos G, Zaharof A.
    Int J Clin Pharmacol Res; 2002 Jul; 22(3-4):85-8. PubMed ID: 12837045
    [Abstract] [Full Text] [Related]

  • 36. An increase in plasma adiponectin multimeric complexes follows hypocaloric diet-induced weight loss in obese and overweight pre-menopausal women.
    Polak J, Kovacova Z, Jacek M, Klimcakova E, Kovacikova M, Vitkova M, Kuda O, Sebela M, Samcova E, Stich V.
    Clin Sci (Lond); 2007 Jun; 112(11):557-65. PubMed ID: 17201694
    [Abstract] [Full Text] [Related]

  • 37. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease.
    Vilar Gomez E, Rodriguez De Miranda A, Gra Oramas B, Arus Soler E, Llanio Navarro R, Calzadilla Bertot L, Yasells Garcia A, Del Rosario Abreu Vazquez M.
    Aliment Pharmacol Ther; 2009 Nov 15; 30(10):999-1009. PubMed ID: 19691668
    [Abstract] [Full Text] [Related]

  • 38. Effect of orlistat on fecal fat, fecal biliary acids, and colonic cell proliferation in obese subjects.
    Ahnen DJ, Guerciolini R, Hauptman J, Blotner S, Woods CJ, Wargovich MJ.
    Clin Gastroenterol Hepatol; 2007 Nov 15; 5(11):1291-9. PubMed ID: 17920338
    [Abstract] [Full Text] [Related]

  • 39. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease.
    Emery MG, Fisher JM, Chien JY, Kharasch ED, Dellinger EP, Kowdley KV, Thummel KE.
    Hepatology; 2003 Aug 15; 38(2):428-35. PubMed ID: 12883487
    [Abstract] [Full Text] [Related]

  • 40. The add-on effects of Gynostemma pentaphyllum on nonalcoholic fatty liver disease.
    Chou SC, Chen KW, Hwang JS, Lu WT, Chu YY, Lin JD, Chang HJ, See LC.
    Altern Ther Health Med; 2006 Aug 15; 12(3):34-9. PubMed ID: 16708768
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 38.